Cover Image
市場調查報告書

EpiCast Report:乾燥症(修格蘭氏症候群) (SS) - 到2024年前的流行病學預測

EpiCast Report: Sjogren's Syndrome - Epidemiology Forecast to 2024

出版商 GlobalData 商品編碼 349803
出版日期 內容資訊 英文 52 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:乾燥症(修格蘭氏症候群) (SS) - 到2024年前的流行病學預測 EpiCast Report: Sjogren's Syndrome - Epidemiology Forecast to 2024
出版日期: 2015年12月09日 內容資訊: 英文 52 Pages
簡介

全球主要7國(美國,法國,德國,義大利,西班牙,英國,日本)確診乾燥症(修格蘭氏症候群) (SS)的患者數,預測將從2014年的3,210,390人成長到2024年的3,533,298人,以1.01%的年度成長率增加。

本報告提供全球主要7個國家的乾燥症(修格蘭氏症候群) (SS) 調查分析,提供您疾病背景,危險因素和合併症,全球趨勢,流行病學預測等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 危險因素和合併症
  • 全球趨勢
    • 主要7個國家
    • EU5個國家
    • 日本
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法
  • SS的流行病學預測
    • SS和確診的患者數
    • SS和確診的患者數 (各年齡)
    • SS和確診的患者數 (性別)
    • SS和確診的患者數 (年齡標準化) 、等
  • 議論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表

目錄
Product Code: GDHCER104-15

Sjogren's syndrome (SS) is a chronic systemic autoimmune disease characterized by chronic inflammation of the exocrine glands and is one of the three most common autoimmune diseases in the US. Due to the lack of validated and universally accepted diagnostic criteria for diagnosing SS, a large variation can be seen in the rates of this disease. The three most commonly utilized diagnostic criteria for SS include the Copenhagen criteria, the European classification criteria, and the International Collaborative Clinical Alliances Cohort (SICCA) criteria. The European classification criteria, which were revised by the American-European Consensus Group (AECG), are currently the most widely used diagnostic criteria. Even though no cure currently exists for SS, treatments are used to manage the symptoms and prevent further complications. These might include the use of salivary substitutes and artificial tears, or in the case of secondary SS, treatment of the underlying disease.

GlobalData epidemiologists estimate that within the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, Japan), as shown in Figure 1, the diagnosed prevalent cases of SS will increase from 3,210,390 cases in 2014 to 3,533,298 cases in 2024, at an Annual Growth Rate (AGR) of 1.01% over the forecast period. Throughout the forecast period, the US will have the highest number of diagnosed prevalent cases of SS in the 7MM. Similarly, the diagnosed prevalent cases of primary Sjogren's syndrome (pSS) will increase from 2,161,973 cases in 2014 to 2,384,551 cases in 2024, while the diagnosed prevalent cases of secondary Sjogren's syndrome (sSS) will increase from 1,048,417 cases in 2014 to 1,148,874 cases in 2024. During the forecast period, the proportion of ocular manifestations in the diagnosed prevalent cases of SS will range from a low of 87.00% in the UK and the US to a high of 98.00% in Italy. Similarly, approximately, 93.00-96.00% of prevalent SS cases will experience oral symptoms during the forecast period.

Scope

  • The Sjogren's Syndrome (SS) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for SS, which includes both primary Sjogren's syndrome (pSS) and secondary Sjogren's syndrome (sSS), in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of pSS, segmented by sex and age (from 18-19 years, then in 10-year age groups), diagnosed prevalent cases of sSS as well as SS and cases of ocular and oral manifestations in SS, in these markets.
  • The SS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The SS EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global SS market.
  • Quantify patient populations in the global SS market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for SS therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. 7MM Diagnosed Prevalent Cases
    • 3.3.2. 5EU Diagnosed Prevalent Cases
    • 3.3.3. Japan Diagnosed Prevalent Cases
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast for SS (2014-2024)
    • 3.5.1. Diagnosed Prevalent Cases of SS
    • 3.5.2. Age-Specific Diagnosed Prevalent Cases of pSS
    • 3.5.3. Sex-Specific Diagnosed Prevalent Cases of pSS
    • 3.5.4. Age-Standardized Diagnosed Prevalence of pSS
    • 3.5.5. Ocular and Oral Manifestations
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for SS
  • Table 2: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of pSS
  • Table 3: 7MM, Sources Used to Forecast the Oral and Ocular Manifestations of SS
  • Table 4: 7MM, Sources Not Used in the Epidemiological Analysis of SS
  • Table 5: Diagnosed Prevalent Cases of SS, Age ≥18 Years, Both Sexes, N, 2014-2024
  • Table 6: 7MM, Age-Specific Diagnosed Prevalent Cases of pSS, Age ≥18 Years, Both Sexes, N, 2014
  • Table 7: 7MM, Sex-Specific Diagnosed prevalent Cases of pSS, Age ≥18 Years, N, 2014

List of Figures

  • Figure 1: Diagnosed Prevalence Rate of SS in the 7MM, 2014
  • Figure 2: Case Flow Map for pSS: US, Germany, Italy, UK, and Japan
  • Figure 3: Case Flow Map for pSS: France and Spain
  • Figure 4: 7MM, Diagnosed Prevalent Cases of pSS, Age ≥18 Years, Both Sexes, N, Selected Years, 2014-2024
  • Figure 5: 7MM, Diagnosed Prevalent Cases of sSS, Age ≥18 Years, Both Sexes, N, Selected Years, 2014-2024
  • Figure 6: 7MM Diagnosed Prevalent Cases of SS, Age ≥18 Years, Both Sexes, N, Selected Years, 2014-2024
  • Figure 7: 7MM, Age-Specific Diagnosed Prevalent Cases of pSS, Age ≥18 Years, Both Sexes, N, 2014
  • Figure 8: 7MM, Sex-Specific Diagnosed Prevalent Cases of pSS, Age ≥18 Years, N, 2014
  • Figure 9: 7MM, Age-Standardized Diagnosed Prevalence of pSS, Age ≥18 Years , 2014
  • Figure 10: 7MM, Ocular and Oral Manifestations of SS in the Diagnosed Prevalent Cases of SS, Age ≥18 Years , 2014
Back to Top